Efficiency of Subsrachnoid Injection of Dexmedetomidine Combined with Intravenous Dexamethasone for Subarachnoid Block

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114527

Enrollment

Unknown

Registered

2025-12-15

Start date

2025-12-22

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group A:Intravenous dexamethasone, subarachnoid injection of dexmedetomidine + ropivacaine

Group B:Subarachnoid injection of dexmedetomidine + ropivacaine

Group C:Intravenous dexamethasone and subarachnoid injection of ropivacaine

Group D:Subarachnoid injection of ropivacaine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. ASA classification II-III 2. Male or female, aged 18-75 years 3. BMI < 35

Exclusion criteria

Exclusion criteria: 1. Presence of cardiovascular comorbidities; 2. Presence of neurological disorders; 3. History of drug allergies and contraindications to spinal anaesthesia.

Design outcomes

Primary

Measure	Time frame
Time for sensory nerve blockade to subside to S1 level;	—

Secondary

Measure	Time frame
Time to complete resolution of motor nerve block;highest level of sensory nerve block;Complete motor nerve block time;Sedation score;	—

Countries

China

Contacts

Public ContactZhichao Qin

Binzhou Medical College Yantai Affiliated Hospital

254162132@qq.com+86 159 6516 2783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026